regulatory status raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-06-22. Anything still debated is marked as such rather than presented as settled.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
=== Triplexfpp === Triplexfpp is based on deep learning methods. This Python-based pipeline can help predict the most likely triplex-forming lncRNA. However since the lncRNA for training is limited, there is a long way to go before machine learning and deep learning methods can be applied.
== Tissue == Bone is not uniformly solid, but consists of a flexible matrix (about 30%) and bound minerals (about 70%), which are intricately woven and continuously remodeled by a group of specialized bone cells. Their unique composition and design allows bones to be relatively hard and strong, while remaining lightweight. Bone matrix is 90 to 95% composed of elastic collagen fibers, also known as ossein, and the remainder is ground substance. The elasticity of collagen improves fracture resistance. The matrix is hardened by the binding of inorganic mineral salt, calcium phosphate, in a chemical arrangement known as bone mineral, a form of calcium apatite. It is the mineralisation that gives bones rigidity. Within any single bone, the tissue is woven into two main patterns: cortical and cancellous bone, each with distinct appearances and characteristics. Bone is actively constructed and remodeled throughout life by specialized bone cells known as osteoblasts and osteoclasts.
Collagen IV (ColIV or Col4) is a type of collagen found primarily in the basal lamina. The collagen IV C4 domain at the C-terminus is not removed in post-translational processing, and the fibers link head-to-head, rather than in parallel. Also, collagen IV lacks the regular glycine in every third residue necessary for the tight, collagen helix. This makes the overall arrangement more sloppy with kinks. These two features cause the collagen to form in a sheet, the form of the basal lamina. Collagen IV is the more common usage, as opposed to the older terminology of "type-IV collagen". Collagen IV exists in all metazoan phyla, to whom it served as an evolutionary stepping stone to multicellularity. There are six human genes associated with it:
The plutonium present in spent nuclear fuel contains about 12% of 241Pu. Because it beta-decays to 241Am, 241Pu can be extracted and may be used to generate further 241Am. However, this process is rather slow: half of the original amount of 241Pu decays to 241Am after about 15 years, and the 241Am amount reaches a maximum after 70 years. The obtained 241Am can be used for generating heavier americium isotopes by further neutron capture inside a nuclear reactor. In a light water reactor (LWR), 79% of 241Am converts to 242Am and 10% to its nuclear isomer 242mAm:
In February 2010, the FDA's associate director of drug safety, recommended rosiglitazone be taken off the market. In June 2010, they published a retrospective study comparing roziglitazone to pioglitazone, the other thiazolidinedione marketed in the United States and concluded rosiglitazone was associated with "an increased risk of stroke, heart failure, and all-cause mortality and an increased risk of the composite of AMI, stroke, heart failure, or all-cause mortality in patients 65 years or older". The number needed to harm with roziglitazone was sixty. Graham argued rosiglitazone caused 500 more heart attacks and 300 more heart failures than its main competitor. Two meta analyses released in 2010, one incorporating 56 trials and a second incorporating 164 trials reached conflicting conclusions. Nissen et al. found again an increased risk for heart infarction against control, but no increased risk for cardiovascular death. Mannucci et al. found no statistically significant increase in cardiac events but a significant increase in heart failure. A 2011 drug class review found an increased risk of cardiovascular adverse events. A meta-analysis of 16 observational studies released in March, 2011, compared rosiglitazone to pioglitazone, finding support for greater cardiovascular safety for pioglitazone. The meta-analysis involved 810 000 patients taking rosiglitazone or pioglitazone. The study suggests 170 excess myocardial infarctions, 649 excess cases of heart failure, and 431 excess deaths for every 100 000 patients who receive rosiglitazone rather than pioglitazone.
Sources: en.wikipedia.org
Acanthoscurria geniculata, Brazilian whiteknee tarantula (2014) Argiope bruennichi, European wasp spider (2021) Dysdera silvatica, Canary Island nocturnal endemic woodlouse spider (2019) Latrodectus elegans, Black widow spider (2022) Latrodectus hasselti, Redback spider (2026) Latrodectus katipo, Katipō (2026) Leviellus thorelli, sector orb-weaver (2026) Nephila clavipes, (golden silk orb-weaver) (2017) Parasteatoda tepidariorum, (common house spider) (2017) Stegodyphus mimosarum, African social velvet spider (2014) Uloborus diversus, Cribellate orb-weaving spider, (2023) Order Uropygi:
A fibrocyte is an inactive mesenchymal cell, that is, a cell showing minimal cytoplasm, limited amounts of rough endoplasmic reticulum, and lacks biochemical evidence of protein synthesis. The term fibrocyte contrasts with the term fibroblast. Fibroblasts are activated connective tissue cells characterized by synthesis of proteins of the fibrous matrix, particularly the collagens. When tissue is injured, the predominant mesenchymal cells, the fibroblast, have been believed to be derived from the fibrocyte or possibly from smooth muscle cells lining vessels and glands. Commonly, fibroblasts express smooth muscle actin, a form of actin first found in smooth muscle cells and not found in resting fibrocytes. Fibroblasts expressing this form of actin are usually called "myo-fibroblasts." Recently, the term "fibrocyte" has also been applied to a bloodborne cell able to leave the blood, enter tissue and become a fibroblast. As part of the more general topic of stem cell biology, a number of studies have suggested that the blood contains marrow derived cells that can differentiate into fibroblasts. These cells have been reported to express the hematopoietic cell surface markers CD34+, CD45+, as well as collagen. These cells can migrate to wound sites, suggesting a role in wound healing. There are several studies suggesting that fibrocytes mediate wound healing and fibrotic tissue repair.
=== Electromagnetism === In classical electromagnetism, the vacuum of free space, or sometimes just free space or perfect vacuum, is a standard reference medium for electromagnetic effects. Some authors refer to this reference medium as classical vacuum, a terminology intended to separate this concept from QED vacuum or QCD vacuum, where vacuum fluctuations can produce transient virtual particle densities and a relative permittivity and relative permeability that are not identically unity. In the theory of classical electromagnetism, free space has the following properties:
The inquiry will have two areas of focus – a review of the "placement and categorisation" of all inmates at Wandsworth, and an investigation of all people in custody currently charged with terror offences. The UK's first EV-only manufacturing plant begins production at Ellesmere Port, Cheshire. The UK experiences a fourth day of temperatures exceeding 30 °C (86 °F), the highest consecutive number on record for the month of September, with hot weather expected to continue until the weekend. 8 September – The first anniversary of the death of Elizabeth II is marked by gun salutes at Hyde Park and the Tower of London, as well as the release of a short message from Charles III along with a previously unreleased portrait of the Queen taken in 1968. 9 September – Following a four-day manhunt, Daniel Khalife is arrested by the Metropolitan Police in Chiswick, London. 10 September The Sunday Times reports that two men have been arrested under the Official Secrets Act, including a researcher in the UK Parliament accused of spying for China. Mo Farah, considered one of the greatest British athletes of all time, takes part in the final race of his career at age 40, finishing fourth in the Great North Run. The Metropolitan Police confirm that Daniel Khalife has been charged with escaping from Wandsworth Prison. He appears before Westminster Magistrates Court the following day, where he is remanded in custody until 29 September. 11 September The GMB Union confirms that the UK's 400 Wilko stores will close by early October after a bid to rescue the retailer fell through.
=== Expression proteomics === Expression proteomics includes the analysis of protein expression at a larger scale. It helps identify main proteins in a particular sample, and those proteins differentially expressed in related samples—such as diseased vs. healthy tissue. If a protein is found only in a diseased sample then it can be a useful drug target or diagnostic marker. Proteins with the same or similar expression profiles may also be functionally related. There are technologies such as 2D-PAGE and mass spectrometry that are used in expression proteomics.
Sources: en.wikipedia.org
Lasers can cause biological damage due to the properties of their radiation and their sometimes extremely concentrated electromagnetic power. For this reason, lasers must be labeled with standardized warnings depending on the laser class. The classification is based on the DIN standard EN 60825-1, which distinguishes between ranges of wavelengths and exposure times that lead to characteristic injuries and injury thresholds for power or energy density. The CO2-Laser was developed in 1964 by the Indian electrical engineer and physicist Chandra Kumar Naranbhai Patel (*1938) at the same time as the Nd:YAG laser (neodymium-doped yttrium aluminum garnet laser) at Bell Laboratories by LeGrand Van Uitert (1922-1999) and Joseph E. Geusic (*1931) and the Er:YAG laser (erbium-doped yttrium aluminum garnet laser) and has been used in dentistry since the early 1970s. In the hard laser field, two systems in particular are emerging for use in the oral cavity: the CO2 laser for use in soft tissue and the Er:YAG laser for use in dental hard and soft tissue. The goal of soft laser treatment is to achieve biostimulation with low energy densities. The Commission on Radiological Protection strongly recommends that the possession and purchase of class 3B and 4 laser pointers be regulated by law to prevent misuse. This is due to the increase in dangerous dazzle attacks caused by high-power laser pointers. In addition to pilots, these include truck and car drivers, train operators, soccer players, referees, and even spectators at soccer games.
=== Education === Kenyon graduated with honors from the University of Chicago with a Bachelor of Science in physics in 1961 as a member of Phi Beta Kappa. As an undergraduate, he developed an interest in origin of life research after attending the Darwin Centennial Celebration in 1959. He then earned his Ph.D. in biophysics from Stanford University in 1965. His doctoral dissertation was titled, "Photochemistry of DL-phenylalanine". After receiving his doctorate, he completed research as a postdoctoral fellow of the National Science Foundation in chemical biodynamics at the University of California, Berkeley, under Nobel laureate Melvin Calvin. He then was a research associate at the Ames Research Center from 1965 to 1966.
Chronic social defeat stress produces a counterintuitive long-lasting downregulation of prodynorphin mRNA levels in the NAcc (occurring by day 10 of chronic exposure), and this downregulation is reversed by chronic treatment with standard antidepressant medication (imipramine). Despite this molecular downregulation, behavioral signs of stress-induced dysphoria, anhedonia, and anxiety persist and even intensify with repeated stress exposure, indicating that the coupling between dynorphin release and KOR phosphorylation, as well as the downstream consequences of KOR activation, may become sensitized through counter-adaptations in post-receptor signaling or in competing inhibitory circuits. This process involves: § Signaling after internalisation.
=== Precautions === Precaution is needed when taken in individuals with tetracycline hypersensitivity, pregnant women, and children. It has been found to cause fetal harm when administered during pregnancy and therefore is classified as pregnancy category D. In rats or rabbits, tigecycline crossed the placenta and was found in the fetal tissues, and is associated with slightly lower birth weights as well as slower bone ossification. Even though it was not considered teratogenic, tigecycline should be avoided unless benefits outweigh the risks. In addition, its use during childhood can cause yellow-grey-brown discoloration of the teeth and should not be used unless necessary. More so, there are clinical reports of tigecycline-induced acute pancreatitis, with particular relevance to patients also diagnosed with cystic fibrosis. Tigecycline showed an increased mortality in patients treated for hospital-acquired pneumonia, especially ventilator-associated pneumonia (a non-approved use), but also in patients with complicated skin and skin structure infections, complicated intra-abdominal infections and diabetic foot infection. Increased mortality was in comparison to other treatment of the same types of infections. The difference was not statistically significant for any type, but mortality was numerically greater for every infection type with Tigecycline treatment, and thus prompted a black box warning by the FDA.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.